CompletedNot Applicable

Side Effects of Antipsychotic Medications

United States76 participantsStarted 2006-04

Plain-language summary

Medications like olanzapine have been associated with the development of weight gain and diabetes in some patients. It is not known if the increased risk of developing diabetes is a direct effect on insulin or simply related to weight gain. We hope to learn in this study whether or not olanzapine directly slows down insulin secretion from the pancreas, thereby increasing the risk of developing diabetes.

Who can participate

Age range30 Years – 66 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants 30-66 years of age * Body mass index (BMI) \>25 \< 35 kg/m2. * Fasting plasma glucose concentration \< 126 mg/dL * Stable on one of the following psychiatric medication: Olanzapine (Zyprexa®), Ziprasidone (Geodon®), Aripiprazole (Abilify®), or Risperidone (Risperdal®) * Stable on psychiatric medication for at least 3 months Exclusion Criteria: * Medications that directly affect insulin-mediated glucose disposal * Intense suicidal impulses/intent * Alcohol or substance abuse for 3 months. * Major medical problems, i.e., clinically unstable medical disorder or condition; cardiovascular, hepatic, renal, gastrointestinal, pulmonary, endocrine or other systemic disease that would, in the investigator's clinical judgment interfere with the endocrine measures obtained in this study.

Trial details

NCT IDNCT00363181

SponsorStanford University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2011-12

View on ClinicalTrials.gov More Insulin Resistance trials